Risk of congenital anomalies in pregnant users of statin drugs
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
What is already known about this subject • Cholesterol is known to be essential for fetal development. • Statins, which inhibit cholesterol production, have therefore been considered as potential teratogens and are contraindicated in pregnancy. • Data available thus far on the risks of congenital anomalies associated with statin therapy have come from non‐analytic postmarketing surveillance studies. • Given the increasing use of statins in women of childbearing age, there is a need for a population‐based study on the risks of congenital anomalies associated with gestational statin use. What this study adds • In this pharmacoepidemiological study, we determined the risk of congenital anomalies in women who filled prescriptions for statins during the first trimester of pregnancy, compared with women who had stopped statins before pregnancy or those who used fibrates during pregnancy. • We found no evidence of an increased risk of fetal anomalies among first‐trimester statin users, or any discernable pattern of congenital anomalies among live births. • However, in the absence of outcome data on nonlive births, conclusions remain uncertain. Aims: Evidence from animal studies suggests that statin medications should not be taken during pregnancy. Our aim was to examine the association between the use of statins in early pregnancy and the incidence of congenital anomalies. Methods: A population‐based pregnancy registry was built. Three study groups were assembled: women prescribed statins in the first trimester (group A), fibrate/nicotinic acid in the first trimester (group B) and statins between 1 year and 1 month before conception, but not during pregnancy (group C). Among live‐born infants, we selected as cases infants with any congenital anomaly diagnosed in the first year of life. Controls were defined as infants with no congenital anomalies. The rate of congenital anomalies in the respective groups was calculated. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were also calculated. Results: Our study group consisted of 288 pregnant women. Among women with a live birth, the rate of congenital anomalies was 3/64 (4.69%; 95% CI 1.00, 13.69) in group A, 3/14 in group B (21.43%; 95% CI 4.41, 62.57) and 7/67 in group C (10.45%; 95% CI 4.19, 21.53). The adjusted OR for congenital anomalies in group A compared with group C was 0.36 (95% CI 0.06, 2.18). Conclusion: We did not detect a pattern in fetal congenital anomalies or evidence of an increased risk in the live‐born infants of women filling prescriptions for statins in the first trimester of pregnancy. Conclusions, however, remain uncertain in the absence of data from nonlive births.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macintosh, M. C. M., Fleming, K. M., Bailey, J. A., Doyle, P., Modder, J., Acolet, D., Golightly, S., & Miller, A. (2006) · BMJ · doi:10.1136/bmj.38856.692986.ae · Cited by 673
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Verschuren, W. M. M. (1995) · JAMA · doi:10.1001/jama.1995.03530020049031 · Cited by 573
Mortality in a cohort of street youth in Montreal
Roy, É. (2004) · JAMA · doi:10.1001/jama.292.5.569 · Cited by 334
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model
Kumasawa, K., Ikawa, M., Kidoya, H., Hasuwa, H., Saito-Fujita, T., Morioka, Y., Takakura, N., Kimura, T., & Okabe, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011293108 · Cited by 367
Metadata
- Authors
- Ofori, B., Rey, E., & Bérard, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-08-15
- Volume
- 64
- Issue
- 4
- Pages
- 496-509
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2007060398
- Cited by
- 133
- References
- 5
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of congenital anomalies in pregnant users of statin drugs. https://app.cochat.ai/papers/10.1111/j.1365-2125.2007.02905.x
- The paper
- Ofori, B., Rey, E., & Bérard, A. (2007). Risk of congenital anomalies in pregnant users of statin drugs. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2007.02905.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.